Autolus Therapeutics plc
AUTL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.10 | 0.23 | 0.06 | 0.09 |
| FCF Yield | -40.21% | -13.98% | -68.23% | -33.87% |
| EV / EBITDA | -2.87 | -5.96 | 1.31 | -0.64 |
| Quality | ||||
| ROIC | -33.53% | -58.09% | -31.00% | -36.85% |
| Gross Margin | -12.52% | -286.63% | -2,115.37% | -5,421.50% |
| Cash Conversion Ratio | 0.93 | 0.70 | 0.75 | 0.83 |
| Growth | ||||
| Revenue 3-Year CAGR | 17.78% | 4.06% | 53.43% | -19.68% |
| Free Cash Flow Growth | -53.98% | -27.14% | 2.82% | 4.32% |
| Safety | ||||
| Net Debt / EBITDA | -0.30 | 1.19 | 2.64 | 2.19 |
| Interest Coverage | -25.98 | -4.33 | -18.39 | -148.60 |
| Efficiency | ||||
| Inventory Turnover | 2.75 | 0.00 | 9.69 | 12.71 |
| Cash Conversion Cycle | 1,775.86 | 219.34 | 45.26 | 38.15 |